Antiangiogenesis and medical therapy failure in intracranial atherosclerosis

Nestor R Gonzalez1, Raymond Liou2, Florian Kurth3

  • 1Department of Neurosurgery, Cedars Sinai Medical Center, 127 S San Vicente Blvd., Suite A6600, Los Angeles, CA, 90048, USA. nestor.gonzalez@cshs.org.

Angiogenesis
|October 11, 2017
PubMed

Insights

An antiangiogenic profile in patients with intracranial atherosclerotic disease (ICAD) is linked to recurrent strokes and poor outcomes. This finding suggests antiangiogenesis as a potential therapeutic target for ICAD.

Area of Science:

  • Neuroscience
  • Cardiovascular Research
  • Biomarkers

Background:

  • Intracranial atherosclerotic disease (ICAD) is a leading cause of stroke with a poor prognosis.
  • The role of angiogenic factors in ICAD progression and outcomes requires further investigation.

Purpose of the Study:

  • To test the hypothesis that the balance of circulating pro- and antiangiogenic factors influences ICAD disease course.
  • To identify potential biomarkers for ICAD progression and therapeutic targets.

Main Methods:

  • Prospective observational study of 74 patients with severe ICAD.
  • Measurement of 21 angiogenic factors in serum using multiplex ELISA.
  • Analysis of associations between angiogenic profiles and clinical outcomes (stroke recurrence, disability) and angiographic neovascularization.

Main Results:

  • A functionally antiangiogenic profile strongly associated with recurrent stroke or TIA (OR=7.2).
  • This profile independently predicted poor functional status at 6 months (p=0.002).
  • High endostatin and angiostatin levels correlated with low neovascularization in surgical patients (p=0.02).

Conclusions:

  • Antiangiogenesis significantly impacts ICAD patient prognosis.
  • Angiogenic factor profiles may serve as valuable prognostic markers.
  • Targeting antiangiogenesis presents a potential therapeutic strategy for ICAD.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
473
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
352
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.2K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
398
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K